SCHEMBL2552755

SCHEMBL2552755

C=CCc1cc([N+](=O)[O-])ccc1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.55
TDP1 Q9NUW8 4/20 0.55
TSHR P16473 3/20 0.55
CYP3A4 P08684 4/20 0.50
PDE2A O00408 1/20 0.46
PDE5A O76074 1/20 0.46
ALOX15 P16050 1/20 0.46
NFKB1 P19838 1/20 0.46
APEX1 P27695 1/20 0.46
PDE4A P27815 1/20 0.46
BLM P54132 1/20 0.46
PDE1B Q01064 1/20 0.46
PMP22 Q01453 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4D Q08499 1/20 0.46
PDE7A Q13946 1/20 0.46
PDE1C Q14123 1/20 0.46
PDE7B Q9NP56 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.42
POLB P06746 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16975394 0.85 ALDH1A1 (0.56) ALDH1A1TDP1TSHRCYP3A4PDE2A
SCHEMBL4980531 0.83 POLB (0.61) ALDH1A1TDP1TSHRL3MBTL1POLB
SCHEMBL9683795 0.81 TDP1 (0.50) ALDH1A1TDP1TSHRCYP3A4ALOX15
SCHEMBL14768876 0.80 ALDH1A1 (0.64) ALDH1A1TDP1TSHRCYP3A4PDE2A
SCHEMBL10175659 0.80 ALDH1A1 (0.64) ALDH1A1TDP1TSHRCYP3A4PDE2A
SCHEMBL7080073 0.80 PTPRC (0.41) ALDH1A1TDP1TSHRCYP3A4POLB
SCHEMBL27401907 0.80 HSD17B10 (0.55) ALDH1A1TDP1HSD17B10MAPTLMNA
SCHEMBL3958628 0.80 GABRA1 (0.55) ALDH1A1TDP1CYP3A4POLBCYP19A1
SCHEMBL11097917 0.79 TSHR (0.44) ALDH1A1TDP1TSHRPOLBHSD17B10
SCHEMBL4301056 0.79 MEN1 (0.45) ALDH1A1TDP1PDE7APOLBCYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2555623-A1 FLAVIN DERIVATIVES BioRelix, Inc. (US) 2013-02-13 EP disclosed
US-20130029980-A1 FLAVIN DERIVATIVES COISH PHILIP D G (US) 2013-01-31 US disclosed
US-20130029980-A1 FLAVIN DERIVATIVES COISH PHILIP D G (US) 2013-01-31 US disclosed
US-20130029980-A1 FLAVIN DERIVATIVES COISH PHILIP D G (US) 2013-01-31 US disclosed
WO-2011126567-A1 FLAVIN DERIVATIVES BIORELIX, INC. (US) 2011-10-13 WO disclosed
US-20110052643-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2011-03-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029980-A1 FLAVIN DERIVATIVES BLVRB, FLAD1, FDPS ALDH1A1 871/4885TDP1 828/4885TSHR 3098/4885
US-20110052643-A1 COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES TSLP, NFATC1, IL5 ALDH1A1 644/4885TDP1 4423/4885TSHR 4453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.